News Search Results
Sep 11, 2025, 10:00 ET Lilly to participate in Bernstein's 2nd Annual Healthcare Forum
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Sep 11, 2025, 09:41 ET Gene Solutions Secures Patent(1) for Breakthrough Mitochondrial Therapy Platform Targeting Neurological Diseases
board member. "This achievement protects our proprietary inventions and strengthens our position as a collaborator of choice for pharmaceutical and biotechnology partners worldwide." With research expertise spanning the USA and UK, Gene Solutions is dedicated to accelerating
More news about: Gene Solutions
Sep 11, 2025, 09:27 ET GLOBAL FIRST "High-Definition Image": Decoding the "Code of Youth" - LivingPhoenix's POGMENT Collagen Breakthrough Fills Global Gap
of Tokyo, among other institutions, has passed peer review and was published in the SCI Q1 journal Frontiers in Bioengineering and Biotechnology (Impact Factor: 4.8). These milestones mark the technology's entry into a high-standard, high-barrier phase of development. The project
More news about: LivingPhoenix
Sep 11, 2025, 09:00 ET MycoWorks Reaches New Milestone with the Next Iteration of Fine Mycelium™
"mycelium-only" materials MycoWorks is at the forefront of transforming mycelium materials into industrial reality. The company's Fine Mycelium™ biotechnology has rapidly scaled into a platform for fast-paced innovation, building on years of pioneering achievements in mycology, manufacturing and tanning
More news about: MycoWorks
Sep 11, 2025, 08:44 ET SeoulTech Researchers Uncover High PAHs in Common Foods
making it safe, reliable, and efficient for PAH analysis. In a new study, a team of researchers from the Department of Food Science and Biotechnology, Seoul National University of Science and Technology, led by Professor Joon-Goo Lee,
More news about: Seoul National University of Science and Technology (SEOULTECH)
Sep 11, 2025, 08:30 ET Rare Disease Trials, Rarely Ready: Why Most Fail Before They Begin, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 11, 2025, 08:30 ET DNA-Encoded Library Data: Unlocking Chemomic Insights for Drug Discovery, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 11, 2025, 07:43 ET 世界初の「高精細画像」！「青春のコード」を解読--如鳳凰POGMENTコラーゲン成果が国際的空白を埋める
た、如鳳凰が上海交通大学医学院付属第九人民病院、国家老年医学中心北京病院、北京大学第三病院、および東京大学などの機関と共同で作成したオリジナル研究成果は、ピアレビューを経てSCI Q1領域の学術誌「Frontiers in Bioengineering and Biotechnology」（インパクトファクター4.8）に掲載されました。 さらに、本技術成果は国家薬品監督管理局の標準記録に承認され、「組織工学医療機器コラーゲン用語集」（YY/T1955-2025）に掲載、医療機器主要文書登録及び化粧品原料リストにも掲載されている。 将来的には、医療美容およびアンチエイジング、組織工学、慢性創傷治癒、機能性化粧品など多岐にわたるシーンにおいて応用が見込まれ、広範な産業化の展望を有している。
More news about: 如鳳凰
Sep 10, 2025, 15:07 ET Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey
international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India
More news about: Biocon
Sep 10, 2025, 14:30 ET NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced positive initial results from its collaboration with
More news about: NeuroSense
Sep 10, 2025, 09:30 ET Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries
"Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale production of high-purity, highly active free-form soybean phospholipids. This breakthrough was
More news about: Shineco,Inc.
Sep 10, 2025, 08:48 ET Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Sep 10, 2025, 08:43 ET Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Sep 10, 2025, 08:30 ET Tumor Microenvironment Analysis Using Curated Data and Modeling, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 10, 2025, 08:30 ET Patient Recruitment Strategies: Empowering Patients Through Accessible Information, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Sep 10, 2025, 07:47 ET Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update
Sept. 10, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system
More news about: Intensity Therapeutics Inc.
Sep 10, 2025, 07:00 ET Noxilizer Expands Access to Commercial-Scale Nitrogen Dioxide Terminal Sterilization Capacity with $30 Million in Growth Capital Led by NewVale Capital
sterilization platform plays a pivotal role in addressing the urgent market demand for alternatives to ethylene oxide ("EtO"), with leading pharmaceutical, biotechnology, and medical device companies already relying on Noxilizer to sterilize critical drug-device combination products. This growth financing will expand
More news about: Noxilizer, Inc.
Sep 10, 2025, 06:00 ET Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
hurdle required for closing the merger. Upon completion, the combined company — to be known as NewCelX Ltd. — will remain a publicly traded biotechnology company listed on Nasdaq under the ticker "NCEL", uniting Kadimastem's proprietary cell therapy platforms with NLS's expertise in small-molecule
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Sep 10, 2025, 06:00 ET Essa Pharma Inc. to Adjourn Special Meeting to September 29, 2025
September 10, 2025 to consider and approve the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Common Shares (the "Transaction" or the "Arrangement"). ESSA is
More news about: ESSA Pharma Inc.
Sep 09, 2025, 22:49 ET ImmVira Announces First-in-Human Data of Engineered Exosome MVR-EX105 for Fat Reduction and Muscle Preservation by Topical Application at 2025 Annual Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders
professional-grade at-home solutions for localized fat reduction. About ImmVira ImmVira is a global leading clinical-stage biotechnology company that is powered by proprietary biological engineering technology, and is dedicated to the discovery, development, manufacture and commercialization
More news about: ImmVira
![Partner Therapeutics Receives EMA Approval of IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Hematopoietic Sub-syndrome of Acute Radiation Syndrome [H-ARS])](https://mma.prnewswire.com/media/633165/PTx_updated_logo.jpg?w=300){kind=logo}
Sep 09, 2025, 13:42 ET Partner Therapeutics Receives EMA Approval of IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Hematopoietic Sub-syndrome of Acute Radiation Syndrome [H-ARS])
https://ec.europa.eu/health/documents/community-register/2025/20250821166908/anx_166908_en.pdf. ABOUT PARTNER THERAPEUTICSPartner Therapeutics, Inc. (PTx), an integrated biotechnology company, focuses on development and commercialization of late-stage therapeutics to improve health outcomes in treatment serious diseases and to
More news about: Partner Therapeutics, Inc.
Sep 09, 2025, 11:22 ET Marshmallow Market Is Expected To Reach US$3.46 Billion By 2031 At CAGR Of 7.4% During The Forecast Period |The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Sep 09, 2025, 11:00 ET TCI Biotech Strengthens Global Leadership Team with Appointment of Sales VP Tony Hatori and Strategic Consultant Alan Roberts
SALT LAKE CITY, Utah, Sept. 9, 2025 /PRNewswire/ -- TCI, a global biotechnology leader in health and wellness innovation, today announced key leadership appointments to accelerate its international growth. Tony
More news about: TCI; TCI Bio
Sep 09, 2025, 10:43 ET GBI Biomanufacturing Partners with NanoRetinal to Advance Vision-Restoring Therapy for Inherited Retinal Diseases
analytical characterization, and GMP manufacturing of complex biologics. NanoRetinal NanoRetinal is a biotechnology company dedicated to developing life-changing treatments for patients with IRD through applications of their proprietary nanoparticulate technology.
More news about: GBI Biomanufacturing
Sep 09, 2025, 10:05 ET 3D Printing Market to Reach USD 210.5 Billion by 2035 | Growing at a CAGR of 24.25% - Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research